



DEPARTMENT OF HEALTH & HUMAN SERVICES

Food and Drug Administration  
Rockville MD 20857

MAR 3 2010

Re: MULTAQ  
Patent Nos. 5,223,510 and 7,323,493  
Docket Nos. FDA-2010-E-0039  
FDA-2010-E-0040

The Honorable David J. Kappos  
Undersecretary of Commerce for Intellectual Property  
Director of the United States Patent and Trademark Office  
Mail Stop Hatch-Waxman PTE  
P.O. Box 1450  
Alexandria, VA 22313-1450

Dear Director Kappos:

This is in regard to the applications for patent term extension for U.S. Patent Nos. 5,223,510 and 7,323,493 filed by Sanofi-Aventis, under 35 U.S.C. § 156. The human drug product claimed by the patent is MULTAQ (dronedarone hydrochloride), which was assigned new drug application (NDA) Nos. 21-913 and 22-245.

A review of the Food and Drug Administration's official records indicates that this product was subject to a regulatory review period before its commercial marketing or use, as required under 35 U.S.C. § 156(a)(4). Our records also indicate that it represents the first permitted commercial marketing or use of the product, as defined under 35 U.S.C. § 156(f)(1).

The NDA was approved on July 1, 2009, which makes the submission of the patent term extension application on August 20, 2009, timely within the meaning of 35 U.S.C. § 156(d)(1).

Should you conclude that the subject patents are eligible for patent term extension, please advise us accordingly. As required by 35 U.S.C. § 156(d)(2)(A) we will then determine the applicable regulatory review period, publish the determination in the *Federal Register*, and notify you of our determination.

Please let me know if we can be of further assistance.

Sincerely yours,

Jane A. Axelrad  
Associate Director for Policy  
Center for Drug Evaluation and Research

Kappos – MULTAQ  
Patent Nos. 5,223,510 and 7,323,493  
Page 2

cc: John D. Conway  
Sanofi-Aventis U.S. Inc.  
US Patent Operations Mail Code: BWD-303A  
Route #202-206/P.O. Box 6800  
Bridgewater, NJ 08807-0800